• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Considerations regarding an updated meta-analysis of the optimal duration of oxaliplatin-based adjuvant chemotherapy in patients with different risk factors for stage II-III colon cancer.

作者信息

Pang Huayang, Yan Menghua, Chen Lihui, Zhao Zhou, Li Wei, Zhang Shouru, Sun Hao

机构信息

Department of Gastrointestinal Cancer Center, Chongqing University Cancer Hospital.

Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, People's Republic of China.

出版信息

Int J Surg. 2024 Jul 1;110(7):4431-4432. doi: 10.1097/JS9.0000000000001350.

DOI:10.1097/JS9.0000000000001350
PMID:39042074
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11254244/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0115/11254244/0d70be8a6370/js9-110-4431-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0115/11254244/0d70be8a6370/js9-110-4431-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0115/11254244/0d70be8a6370/js9-110-4431-g001.jpg

相似文献

1
Considerations regarding an updated meta-analysis of the optimal duration of oxaliplatin-based adjuvant chemotherapy in patients with different risk factors for stage II-III colon cancer.关于对不同风险因素的II-III期结肠癌患者基于奥沙利铂的辅助化疗最佳疗程进行更新的荟萃分析的考量。
Int J Surg. 2024 Jul 1;110(7):4431-4432. doi: 10.1097/JS9.0000000000001350.
2
The updated five-year overall survival and long-term oxaliplatin-related neurotoxicity assessment of the FACOS study.FACOS 研究更新的五年总生存和长期奥沙利铂相关神经毒性评估。
Surg Today. 2021 Aug;51(8):1309-1319. doi: 10.1007/s00595-021-02230-8. Epub 2021 Feb 14.
3
Optimal duration of adjuvant therapy for stage III colon cancer.III期结肠癌辅助治疗的最佳疗程
Clin Adv Hematol Oncol. 2019 May;17(5):289-298.
4
[Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial].
Strahlenther Onkol. 2016 Jul;192(7):505-6. doi: 10.1007/s00066-016-0991-y.
5
Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.奥沙利铂对比含奥沙利铂与不含奥沙利铂的辅助化疗治疗 III 期结肠癌的疗效比较。
J Natl Cancer Inst. 2012 Feb 8;104(3):211-27. doi: 10.1093/jnci/djr524. Epub 2012 Jan 20.
6
Is oxaliplatin combined with weekly bolus 5-fluorouracil and leucovorin an option for stage II and III colon cancer?奥沙利铂联合每周一次大剂量5-氟尿嘧啶和亚叶酸钙对II期和III期结肠癌患者来说是一种可行的治疗方案吗？
Nat Clin Pract Oncol. 2008 Feb;5(2):72-3. doi: 10.1038/ncponc1006.
7
[II. Postoperative adjuvant chemotherapy for colon cancer. 1. Is oxaliplatin combination the most effective chemotherapy for colon cancer?].[二、结肠癌术后辅助化疗。1. 奥沙利铂联合化疗是结肠癌最有效的化疗方案吗？]
Gan To Kagaku Ryoho. 2012 Nov;39(11):1642-.
8
Effect of delay in adjuvant oxaliplatin-based chemotherapy for stage III colon cancer.奥沙利铂辅助化疗延迟对III期结肠癌的影响。
Clin Colorectal Cancer. 2015 Mar;14(1):25-30. doi: 10.1016/j.clcc.2014.10.002. Epub 2014 Nov 4.
9
Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.氟尿嘧啶、亚叶酸钙和奥沙利铂辅助治疗 II 期至 III 期结肠癌：MOSAIC 研究更新的 10 年生存和结局数据，依据 BRAF 突变和错配修复状态。
J Clin Oncol. 2015 Dec 10;33(35):4176-87. doi: 10.1200/JCO.2015.63.4238. Epub 2015 Nov 2.
10
Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea.辅助 FOLFOX4 化疗在老年 III 期结肠癌患者中的实际疗效：韩国单中心研究。
Jpn J Clin Oncol. 2013 Feb;43(2):132-8. doi: 10.1093/jjco/hys195. Epub 2012 Nov 29.

本文引用的文献

1
Optimal duration of oxaliplatin-based adjuvant chemotherapy in patients with different risk factors for stage II-III colon cancer: a meta-analysis.奥沙利铂为基础的辅助化疗在不同风险因素的 II-III 期结肠癌患者中的最佳持续时间：一项荟萃分析。
Int J Surg. 2024 May 1;110(5):3030-3038. doi: 10.1097/JS9.0000000000001175.
2
Oxaliplatin (3 months 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07.奥沙利铂（3 个月 6 个月）与氟嘧啶辅助治疗 6 个月治疗 II/III 期结肠癌患者：KCSG CO09-07。
J Clin Oncol. 2022 Nov 20;40(33):3868-3877. doi: 10.1200/JCO.21.02962. Epub 2022 Jun 30.
3
Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial.
III 期 ACHIEVE 试验：奥沙利铂和氟嘧啶类辅助治疗 III 期结肠癌患者 3 个月与 6 个月的最终分析。
J Clin Oncol. 2022 Oct 10;40(29):3419-3429. doi: 10.1200/JCO.21.02628. Epub 2022 May 5.
4
Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project.对于高危 II 期和 III 期结肠癌患者，3 个月与 6 个月的辅助 FOLFOX 或 CAPOX 方案：希腊肿瘤研究组（HORG）参与国际辅助化疗持续时间评估（IDEA）项目的疗效结果。
Ann Oncol. 2019 Aug 1;30(8):1304-1310. doi: 10.1093/annonc/mdz193.